IN8bio (NASDAQ:INAB) Stock Rating Upgraded by Wall Street Zen

IN8bio (NASDAQ:INAB - Get Free Report) was upgraded by equities researchers at Wall Street Zen to a "sell" rating in a research report issued to clients and investors on Saturday.

Separately, HC Wainwright lowered their price target on IN8bio from $8.00 to $6.00 and set a "buy" rating on the stock in a report on Friday, March 14th.

IN8bio Stock Up 15.7%

Shares of NASDAQ:INAB opened at $4.17 on Friday. The stock has a fifty day simple moving average of $0.23 and a two-hundred day simple moving average of $0.26. The stock has a market capitalization of $378.52 million, a price-to-earnings ratio of -5.56 and a beta of 0.18. IN8bio has a 12-month low of $2.85 and a 12-month high of $52.20. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.05.

IN8bio (NASDAQ:INAB - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.01). On average, research analysts anticipate that IN8bio will post -0.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IN8bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC boosted its holdings in IN8bio by 296.7% in the fourth quarter. Jane Street Group LLC now owns 115,919 shares of the company's stock worth $30,000 after purchasing an additional 86,696 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of IN8bio by 56.5% in the fourth quarter. Geode Capital Management LLC now owns 515,193 shares of the company's stock worth $133,000 after acquiring an additional 185,919 shares during the period. Sigma Planning Corp grew its holdings in shares of IN8bio by 22.3% in the fourth quarter. Sigma Planning Corp now owns 1,041,380 shares of the company's stock worth $268,000 after acquiring an additional 190,100 shares during the period. Alyeska Investment Group L.P. grew its holdings in shares of IN8bio by 1,064.5% in the fourth quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company's stock worth $1,302,000 after acquiring an additional 4,628,482 shares during the period. Finally, Franklin Resources Inc. bought a new stake in shares of IN8bio in the fourth quarter worth $1,465,000. Hedge funds and other institutional investors own 92.05% of the company's stock.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.